V-Bio Ventures Closes Second Fund, at EUR 110M
- V-Bio Ventures, a Ghent, Belgium-based independent venture capital firm focused on biotech, closed its second fund, V-Bio Fund 2, at EUR 110m
- Almost all limited partners of their first fund are participating in this second fund, as are multiple new investors
- Together with the first fund, V-Bio Fund 1, V-BioVentures will have over EUR 185m under management
- V-BioVentures focuses specifically on the segment of young pioneering biotech companies and its strategy to invest in transformational companies in the medical and agricultural sectors
- Shelley Margetson joined the fund as Managing Partner, bringing her expertise as senior executive in multiple European biotechnology companies, including Nasdaq-listed Merus
